These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8864800)

  • 1. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition.
    Kuzniar J; Splawinska B; Malinga K; Mazurek AP; Splawinski J
    Int J Clin Pharmacol Ther; 1996 Aug; 34(8):357-61. PubMed ID: 8864800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood.
    Heptinstall S; May JA; Glenn JR; Sanderson HM; Dickinson JP; Wilcox RG
    Thromb Haemost; 1995 Nov; 74(5):1310-5. PubMed ID: 8607115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of platelet antagonists on the ex vivo inhibitory effects of platelet aggregation].
    Sakata T; Kobayashi K; Katayama Y; Takada T; Matsuyama T
    Rinsho Byori; 1991 Mar; 39(3):315-20. PubMed ID: 2051607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and potency of antiplatelet activity of ticlopidine is increased by aspirin.
    Splawinska B; Kuzniar J; Malinga K; Mazurek AP; Splawinski J
    Int J Clin Pharmacol Ther; 1996 Aug; 34(8):352-6. PubMed ID: 8864799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
    Thebault JJ; Kieffer G; Lowe GD; Nimmo WS; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():9-14. PubMed ID: 10440416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacodynamics of clopidogrel.
    Thebault JJ; Kieffer G; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():3-8. PubMed ID: 10440415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
    Savcic M; Hauert J; Bachmann F; Wyld PJ; Geudelin B; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():15-9. PubMed ID: 10440417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
    Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
    Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of rabbit platelet function on simultaneous administration of ticlopidine hydrochloride and OKY-046.
    Kosugi T; Nakamura M; Saitoh S; Kinjoh K
    Int J Tissue React; 1991; 13(3):123-9. PubMed ID: 1960013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.
    Hochholzer W; Trenk D; Frundi D; Blanke P; Fischer B; Andris K; Bestehorn HP; Büttner HJ; Neumann FJ
    Circulation; 2005 May; 111(20):2560-4. PubMed ID: 15809367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K; Kondo K; Ikeda Y; Nakashima M
    Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate.
    Cattaneo M; Akkawat B; Lecchi A; Cimminiello C; Capitanio AM; Mannucci PM
    Thromb Haemost; 1991 Dec; 66(6):694-9. PubMed ID: 1665598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
    Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.